# A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07669415/  
OnCo record `nct07669415` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tislelizumab and Docetaxel in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07669415 by LaNova Medicines Limited, with 108 participants planned, started 2026-07-29 and due to reach its primary completion in 2027-12-15. Interventions recorded: LM-168, Tislelizumab and Docetaxel injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07669415
- Phase: 2
- Setting: A Phase II，Open Label,Multicenter Study to Evaluate the Efficacy,Safety,and Tolerability of LM-168 Combined With Other Anti-tumor Therapies in Participants With Advanced Solid Tumor Trials
- Sponsor: LaNova Medicines Limited
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT07669415: https://clinicaltrials.gov/study/NCT07669415

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07669415.json